Darapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model
Open Access
- 1 April 2018
- journal article
- Published by Walter de Gruyter GmbH in Endocrine Regulations
- Vol. 52 (2) , 69-75
Abstract
Objective. Increase in the low-density lipoprotein (LDL) level in diabetes mellitus and atherosclerosis is related to lipoprotein associated phospholipase A2 (Lp-PLA2). Lp-PLA2 is an enzyme that produces lysophosphatidylcholine (LysoPC) and oxidized nonesterified fatty acids (oxNEFA). LysoPC regulates inflammation mediators, including intra-cellular adhesion molecule-1 (ICAM-1). Darapladib is known as a Lp-PLA2 specific inhibitor. The aim of this study was to reveal the effect of darapladib on the foam cell number, inducible nitric oxide synthase (iNOS), and ICAM-1 expression in aorta at early stages of the atherosclerosis in type 2 diabetes mellitus Sprague-Dawley rat model. Methods. Thirty Sprague-Dawley male rats were divided into 3 main groups: control, rats with type 2 diabetes mellitus (T2DM), and T2DM rats treated with darapladib (T2DM-DP). Each group was divided into 2 subgroups according the time of treatment: 8-week and 16-week treatment group. Fasting blood glucose, insulin resistance, and lipid profile were measured and analyzed to ensure T2DM model. The foam cells number were detected using hematoxylin-eosin (HE) staining and the expression of iNOS and ICAM-1 was analyzed using double immunofluorescence staining. Results. Induction of T2DM in male Sprague-Dawley rats after high fat diet and streptozotocin injection was confirmed by elevated levels of total cholesterol and LDL and increased fasting glucose and insulin levels compared to controls after both times of treatment. Moreover, T2DM in rats induced a significant increase (pConclusion. Our data indicate that darapladib can decrease the foam cells number, iNOS, and ICAM-1 expression in aorta at the early stages of atherosclerosis in T2DM rat model.Keywords
This publication has 20 references indexed in Scilit:
- Targeting the Unstable Plaque in Acute Coronary SyndromesClinical Therapeutics, 2013
- Mechanisms for Insulin Resistance: Common Threads and Missing LinksCell, 2012
- Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2 (Lp-PLA2 ): a reviewLipids in Health and Disease, 2011
- Inhibition of Lipoprotein-Associated Phospholipase A2 Ameliorates Inflammation and Decreases Atherosclerotic Plaque Formation in ApoE-Deficient MicePLOS ONE, 2011
- Endothelial Dysfunction in DiabetesDiabetes Care, 2011
- Proinflammatory Cytokine and Chemokine Gene Expression Profiles in Subcutaneous and Visceral Adipose Tissue Depots of Insulin-Resistant and Insulin-Sensitive Light Breed HorsesJournal of Veterinary Internal Medicine, 2010
- Diabetes and atherosclerosis: is there a role for hyperglycemia?Journal of Lipid Research, 2009
- Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque developmentNature Medicine, 2008
- Leukocyte-endothelial cell interactions are linked to vascular permeability via ICAM-1-mediated signalingAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- Vascular Adhesion Molecules in AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2007